Please assess the completion status of the following clinical trial:

Trial Title: Tacrolimus/Sirolimus Versus Tacrolimus/Mycophenolate Mofetil (MMF) Versus Neoral/Sirolimus in Adult, Primary Kidney Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>14 years~* Weight \> 40 kg~* Primary renal allograft: cadaveric or mismatched living donor~* Negative standard cross match for T-cells~* Women of childbearing potential will be required to have a negative qualitative serum pregnancy test and agree to use an adequate method of contraception throughout the study period and for 3 months after discontinuation of study medication (3yrs, 3 mos.)~* Signed and dated informed consent (Parent or legal guardian must provide written consent for patients \<18 years of age)~Exclusion Criteria:~* Evidence of systemic infection~* History of malignancy within 10 years (with the exception of localized skin cancer)~* Use of any investigational drug or treatment up to 4 weeks prior to enrolling in the study and during the 12-month treatment phase~* Concurrent use of astemizole, pimozide, cisapride, terfenadine, or ketoconazole~* Known hypersensitivity to sirolimus and its derivatives~* Patients with a screening/baseline (or within 96 hours of transplant)~  * total white blood cell count \< 4000/mm3;~ * platelet count \< 100,000/mm3;~ * fasting triglycerides \> 400 mg/dl (\> 4.6 mmol/L);~ * fasting total cholesterol \> 300 mg/dl (\> 7.8 mmol/L);~ * fasting HDL-cholesterol \< 30 mg/dl;~ * fasting LDL-cholesterol \> 200mg/dl

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Tacrolimus/Sirolimus
- B (Type: EXPERIMENTAL): Tacrolimus/MMF
- C (Type: EXPERIMENTAL): Neoral/Sirolimus

Based on this trial design, predict the completion outcome and termination type (if applicable).